In this month's journal, we will examine the important issue of balancing the need for evidence with the imperative for innovation, as well as the ethical and regulatory climates in which these forces must coexist. We are planning to host important conversations such as this in future issues of the journal as well, as an open dialogue on matters critical to the specialty will help to engage and inform our readers. The present discussion was spearheaded by an editorial by Rosenfeld in April 2014 that examined how medicine deals with new devices, some of which he described as "gizmos." 1 In his commentary, Rosenfeld pointed out that many devices or techniques that have been introduced into medicine have historically been shown to be of little value yet have been promoted by physicians for a variety of reasons, some ethical and many not. He drew comparison to some more recent examples from otolaryngology and cautioned for a rational, considered approach to adoption of new technology.
Rosenfeld's brief editorial raises several issues and questions. How do we know when we have enough information to make a decision? How should innovation be rolled out in medicine? What is the role of the physician's autonomy and its appropriate consideration of patient safety, transparency, and consent? How does academic research become adopted in the clinical setting? How should regulation be applied in setting standards for innovative technologies and procedures? Can an appropriate balance be struck that will facilitate innovative medical techniques yet protect core values of medical ethics and patient rights? Difficult questions, indeed, and thoughtful minds may differ with the best of intentions.
One significant issue influencing the adoption of innovative techniques is the importance of full, informed consent of patients in the use of new technology. Surgeons currently may decide to use a specific device or instrument "off-label," with the thought that this methodology could offer clear advantage over other current techniques. Unfortunately, this decision is often made unilaterally and without full participation of the patient or guardian. Compounding this situation even further is that many of these informal "trials" are done outside of a research protocol and without independent review, approval, and oversight of an ethics or institutional review board. Papers in 2 surgical journals highlight this problem. Burger and colleagues 2 discuss the importance of evaluating ethical issues in evidence-based surgical practice, emphasizing the critical role of informed consent and balancing competing ethical interests. In addition, Lee Char and associates 3 examined survey results of surgeons and their patients to evaluate what each constituency considered important and relevant for disclosure around innovative procedures. The authors note that both patients and surgeons agree that it is important to disclose the novel nature of the technique, the potentially unknown risks and benefits, and the surgeon's individual experience with the new procedure. The authors also note that patients, when compared with surgeons, place a higher value on full, open information regarding the use of these procedures, especially around whether the surgeon had ever performed the procedure previously. They conclude, "To promote informed decisionmaking and autonomy among patients considering innovative surgery, surgeons should disclose the novel nature of the procedure, potentially unknown risks and benefits, and whether the surgeon would be performing the procedure for the first time." 3(p473) These papers illustrate that as otolaryngologists adopt new technologies, they must do so with the patient's full, open, and informed consent and with a careful review of their outcomes under appropriate ethical oversight. To be sure, the vast majority of practicing physicians are highly ethical and are clearly motivated to provide outstanding, effective, and safe care to their patients. Ethical lapses, however, have occurred (the Tuskegee syphilis studies are a glaring example of ethical misconduct), and oversight by independent ethics boards can assist with balancing the physician's ethical duty to the patient with his or her desire to advance the quality of medical and surgical care and other relevant conflicts of interest. While some might see this oversight as burdensome, it positions us as physicians in the moral high ground and provides an independent evaluation to buffer claims that competing, sometimes perverse, incentives are driving our medical decision making.
Another issue that complicates the adoption of innovative medical and surgical devices is the Food and Drug Administration's (FDA's) process for "clearing" new devices, through a process known as 510(k). Under this section of the Federal Food, Drug, and Cosmetic Act, manufacturers seek permission to market their device in the United States based on its similarity to a predicate device, or one that has been previously cleared for sale. The degree of similarity is reviewed by the FDA, which then can authorize the device for marketing. Contrary to popular belief, the FDA does not actually approve these devices but rather clears them for marketing and sale. 4 At the time of clearance, therefore, the specific device has not necessarily been tested for safety or efficacy but is authorized for sale based on evidence provided for similar devices, which may or may not be used for similar indications. The use of this 510(k) process has recently come under pressure with the use of power morcellators for uterine fibroids, which has been shown to be associated with increased risk of seeding of uterine cancers in patients with concurrent leiomyosarcoma. 5 In a series of papers published in the Wall Street Journal, it was noted that these devices were cleared for use in uterine surgery based on predicate devices cleared for use in orthopedic joint surgery. Unfortunately, no safety studies were done prior to clearance for use in uterine fibroids, and postrelease safety studies were not conducted for many years. As a result of these types of incidents, the prestigious Institute of Medicine (IOM), in a report commissioned by the FDA, has recommended that the 510(k) process be abolished and replaced by a more rigorous safety and efficacy assessment, much like that used for the introduction of pharmaceutical products in the United States. 6 These recommendations are also discussed by Challoner and Vodra 7 in a recent issue of the New England Journal of Medicine.
On the other hand, there is clearly a moral imperative for medicine to develop better, more effective, and less costly treatment approaches designed to improve health and decrease suffering. To that end, there must be a reasonable climate that balances the need for evidence and the value of innovation within an environment of appropriate oversight and regulation. There are themes that emerge from the IOM report that can assist with a rational approach to facilitating innovation. Curfman and Redberg 8 argue for a balance between regulation and innovation that facilitates the introduction of safe and effective devices, noting "true innovation requires that safety and effectiveness be proven by scientific study in clinical trials." They support rational changes in the current 510(k) process that would eliminate "multiple predicates"-clearances based on prior predicate clearances-as well as a formal, mandatory system of postmarketing surveillance that can allow rapid identification if problems occur. In addition, in response to these concerns, the FDA has adopted an Innovation Pathway that is designed to improve how the FDA and innovators work together. 9 Through this pathway, the FDA has committed to developing "ways to facilitate innovation without compromising our standards and patient safety." It will continue to be important for innovation to flourish in a climate of patient safety and demonstrated efficacy through appropriate regulation and oversight.
It is clear that Rosenfeld's editorial has prompted considerable discussion, which has focused attention on the important issue of balancing evidence and innovation. Many of the concerns raised by this editorial are highlighted in a letter to the editor by Koltai, also presented in this issue. 10 To further explore various viewpoints and aspects of this important discussion, we have invited a series of commentaries from academic and private otolaryngologists to offer their input into the dialogue. In addition, we offer a historical piece by Xu and Shuman, 11 which discusses a "gizmo" from an earlier time and raises awareness of the critical issues involved.
This series of commentaries examines the current climate of evidence, innovation, and regulation and how it affects the practice of our otolaryngology colleagues in both the academic and private sectors. I hope that you will find the conversation interesting and meaningful and that it will stimulate you to further consider its implications and to contribute to the discussion. We will plan to feature similar conversations around important issues facing otolaryngology in upcoming issues. Enjoy your reading!
